34 hospitals, 431 pharma stores suspended from RGHS for fraud in three months

Jaipur:  The health department Friday reported major action against irregularities in the Rajasthan Govt Health Scheme (RGHS), suspending 34 hospitals and 431 pharma stores over the past three months. The department also suspended 28 govt employees and registered 17 FIRs for misuse of the scheme.

Officials said multiple complaints were received about hospitals, medical stores and govt employees engaging in fraudulent practices that harmed the scheme’s functioning. A special audit and intensive investigation were conducted, following which strict action was taken against all entities found prima facie guilty.

An Anti-Fraud Cell has now been set up to curb future violations, and a new SOP will soon be issued to strengthen monitoring, health minister Gajendra Singh Khimsar said.

According to the report, the RGHS office increased surveillance in recent months to protect the treasury and ensure smooth functioning of the scheme. During this period, cases surfaced of private hospitals, approved pharma stores and even beneficiaries availing benefits through improper and rule-violating methods, causing substantial financial losses.

Principal secretary (health) Gayatri Rathore said 34 hospitals were suspended after being found involved in practices such as raising double claims for a single surgery, conducting unnecessary tests and billing higher-rate test packages instead of lower-rate available options. Penalties amounting to Rs 36 crore have been recovered from these hospitals so far.

Similarly, 431 pharma stores were suspended for issuing fake bills and misusing RGHS benefits through collusion between pharmacists, doctors and beneficiaries. The department recovered Rs 4.6 crore in penalties in these cases. More than 1,000 RGHS beneficiary cards used in fraudulent claims have also been blocked, while 28 employees involved in misuse have been suspended.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit